Research of ribomomal protein L23 in tumor progression

doi:10.3760/cma.j.issn.1673-422X.2016.11.008

Abstract

Abstract: Ribosomal protein L23 is a new target for gene therapy of cancer. It participates in tumor progression by activating p53, inactivating murine double minute 2, regulating the carcinogenic activity of cMyc, inducing the multidrug resistance, and affecting the biologic behaviour of tumors. Generally, it′s considered to be a potential prognostic factor in human cancers.

Key words: Neoplasms, Genes, p53, Genes, myc, Drug resistance,multiple, Ribosomal protein L23

Peng Wenmiao, Qin Chuanrong, Zhang Zhimin, Hu Meng, Rao Zhiguo. Research of ribomomal protein L23 in tumor progression[J]. Journal of International Oncology, 2016, 43(11): 835-837.

References

［1］ Klinge S, VoigtsHoffmann F, Leibundgut MA. Atomic structures of the eukaryotic ribosome［J］. Trends Biochem Sci, 2012, 37(5): 189-198. DOI: 10.1016/j.tibs.2012.02.007. ［2］ Zhou X, Liao WJ, Liao JM, et al. Ribosomal proteins: functions beyond the ribosome［J］. J Mol Cell Biol, 2015, 7(2): 92-104. DOI: 10.1093/jmcb/mjv014. ［3］ Vijayakumaran R, Tan KH, Miranda PJ, et al. Regulation of mutant p53 protein expression［J］. Front Oncol, 2015, 5: 284. DOI: 10.3389/fonc, 2015, 5(12): 00284. ［4］ KarniSchmidt O, Lokshin M, Prives C. The roles of MDM2 and MDMX in cancer［J］. Annu Rev Pathol, 2016, 11(5): 617-644. DOI: 0.1146/annurevpathol012414040349. ［5］ Yu Q, Li Y, Mu K, et al. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations［J］. Diagn Pathol, 2014, 9(1): 1-8. DOI: 10.1186/17461596971. ［6］ Michalk M, Meinrath J, Künstlinger H, et al. MDM2 gene amplification in esophageal carcinoma［J］. Oncol Rep, 2016, 35(4): 2223-2227. DOI: 10.3892/or.2016.4578. ［7］ Javid J, Mir R, Julka PK, et al. Association of p53 and mdm2 in the development and progression of non-small cell lung cancer[J]. Tumour Biol, 2015, 36(7): 5425-5432. DOI: 10.1007/s13277-015-3208-6. [8] Zhuo X, Ye H, Li Q, et al. Is mdm2 SNP309 variation a risk factor for head and neck carcinoma?: An updated meta-analysis based on 11 552 individuals[J]. Medicine, 2016, 95(9): e2948. DOI: 10.1097/MD.0000000000002948. ［9］ Burgess A, Chia K M, Haupt S, et al. Clinical overview of MDM2/Xtargeted therapies［J］. Front Oncol, 2016, 6: 7. DOI: 10.3389/fonc.2016.00007. ［10］ Liu Y, Deisenroth C, Zhang Y. RPMDM2p53 pathway: linking ribosomal biogenesis and tumor surveillance［J］. Trends in Cancer, 2016, 2(4): 191204. DOI: 10.1016/j.trecan.2016.03.002. ［11］ Zhang YF, Zhang BC, Zhang AR, et al. Cotransduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviralmediated p53 gene transfer in human gastric cancer［J］. Oncol Rep, 2013, 30(4): 1989-1995. DOI: 10.3892/or.2013.2663. ［12］ Fang HH, Kang JB, Du R, et al. Growth inhibitory effect of adenovirusmediated tissuetargeted expression of ribosomal protein L23 on human colorectal carcinoma cells［J］. Oncol Rep, 2015, 34(2): 763770. DOI: 10.3892/or.2015.4026. ［13］ Burgess A, Chia KM, Haupt S, et al. Clinical overview of MDM2/Xtargeted therapies［J］. Front Oncol, 2015, 6: 7. DOI: 10.3389/fonc.2016.00007. ［14］ Jung JH, Liao JM, Zhang Q, et al. Inauhzin3(c) inactivates cMyc independently of p53［J］. Cancer Biol Ther, 2015, 16(3): 412-419. DOI: 10.1080/15384047.2014.1002698. ［15］ Bretones G, Delgado MD, León J. Myc and cell cycle control［J］. Biochim Biophys Acta, 2015, 1849(5): 506-516. DOI: 10.1016/j.bbagrm.2014.03.013. ［16］ Sodir NM, Lamorna BS, Karnezis AN, et al. Endogenous Myc maintains the tumor microenvironment［J］. Genes Dev, 2011, 25(9): 907-916. DOI: 10.1101/gad.2038411. ［17］ Van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis［J］. Nat Rev Cancer, 2010, 10(4): 301-309. DOI: 10.1038/nrc2819. ［18］ Zhou X, Hao Q, Liao JM, et al. Ribosomal protein S14 negatively regulates cMyc activity［J］. J Biol Chem, 2013, 288(30): 21793-21801. DOI: 10.1074/jbc.M112.445122. ［19］ Liao JM, Zhou X, Gatignol A, et al. Ribosomal proteins L5 and L11 cooperatively inactivate cMyc via RNAinduced silencing complex［J］. Oncogene, 2014, 33(41): 4916-4923. DOI: 10.1038/onc.2013.430. ［20］ Wanzel M, Russ AC, KleineKohlbrecher DA, et al. A ribosomal protein L23nucleophosmin circuit coordinates Miz1 function with cell growth［J］. Nat Cell Biol, 2008, 10(9): 1051-1061. DOI: 10.1038/ncb1764. ［21］ Vo BT, Wolf E, Kawauchi D, et al. The interaction of Myc with Miz1 defines medulloblastoma subgroup identity［J］. Cancer Cell, 2016, 29(1): 5-16. DOI: 10.1016/j.ccell.2015.12.003. ［22］ Shi Y, Zhai H, Wang X, Han Z, et al. Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing druginduced apoptosis［J］. Exp Cell Res, 2004, 296(2): 337-346. DOI: 10.1016/j.yexcr.2004.02.009. ［23］于海燕, 张志勇, 王凯, 等. 下调RPL23对胃癌耐药细胞SGC7901/ADR药物敏感性的影响［J］. 现代肿瘤医学, 2015, 23(10): 1340-1343. ［24］吴静, 杨睿, 刘树业. 肿瘤多药耐药的产生机制及逆转策略［J］. 国际肿瘤学杂志, 2013, 40(12): 889-892. DOI: 10.3760/cma.j.issn.1673-422X.2013.12.003. ［25］ Salehan MR, Morse HR. DNA damage repair and tolerance: a role in chemotherapeutic drug resistance［J］. Br J Biomed Sci, 2013, 70(1): 31-40. ［26］ Wu L, Li X, Xu F, et al. Overexpression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine［J］. Ann Hematol, 2012, 91(10): 1547-1554. DOI: 10.1007/s00277-012-1486-2. ［27］ de Las HerasRubio A, Perucho L, Paciucci R, et al. Ribosomal proteins as novel players in tumorigenesis［J］. Cancer Metastasis Rev, 2014, 33(1): 115-141. DOI: 10.1007/s10555-013-9460-6.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.